The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Overcoming resistance to immunotherapy in lung cancer
Alessandra Curioni-Fontecedro, MD, Cantonal Hospital of Fribourg, Fribourg, Switzerland, discusses the major challenges faced by thoracic oncologists, including resistance to immunotherapy in patients with non-small cell lung cancer. Dr Curioni-Fontecedro highlights the need for new combinations to transform “cold” tumors into “hot” tumors that respond to immunotherapy, and notes that ongoing studies are investigating ways to overcome resistance, including combining treatments that target the immune system and blood vasculature. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
